Page 140 - CW E-Magazine (24-9-2024)

Pharmaceuticals Pharmaceuticals

DRIVING INNOVATION AFFORDABLE MEDICATION
Laurus Labs opens new R&D facility in Genome Vally Bharat Biotech collaborates with Alopexx for anti-microbial

Laurus Labs has formally opened Laurus, with revenues of vaccine
a new research & development (R&D) Rs. 6,041-crore in FY24, is in the
centre in Hyderabad’s Genome Valley manufacture of active pharmaceutical Bharat Biotech Ltd. has collabo- novel, broad-spectrum immune-mediated a wide range of PNAG-expressing
that will support the contract develop- ingredients (APIs) and formulations. rated with US-based Alopexx for the therapeutics for the prevention and treat- pathogens, reaffi rming its potential as a
ment and manufacturing organisation It has leadership in certain anti-retro- co-development and commercialisation ment of bacterial, fungal, and parasitic broad-spectrum antimicrobial solution,
(CDMO) business of the generic drug- viral and high potent oncology APIs. of Alopexx’s proprietary broad-spec- infections. the statement said.
maker. The company is also investing heavily trum anti-microbial vaccine, AV0328,
in building its CDMO business, offering in India and other low-income and lower- AV0328 is a synthetic vaccine Dr. Krishna Ella, Executive Chair-
Telangana’s Industries and IT Mini- clinical phase drug development to middle-income countries. According to designed to target poly N-acetyl man of Bharat Biotech, commented,
ster, Mr. D. Sridhar Babu, inaugurated commercial manufacturing services, to a statement from Bharat Biotech, “As glucosamine (PNAG), a substance found “Our goal is to develop solutions to
the centre, located in IKP Knowledge The facility is designed to foster global innovators. part of the collaboration, the compa- on the surface of a wide range of bacte- reduce antimicrobial resistance through
Park, in the presence of Laurus Labs innovation and advance the company’s nies will co-develop and commercialise rial, fungal, and parasitic pathogens, the vaccination. This collaboration aligns
founder and CEO, Mr. Satyanarayana mission of developing ‘Chemistry for The Minister’s offi ce, in a release AV0328, a synthetic vaccine targeting statement said. In preclinical studies, tar- with our mission to provide safe,
Chava and others. Better Living’. said, said Laurus had recently announced poly N-acetyl glucosamine (PNAG), geting PNAG has shown effectiveness affordable, and high-quality vaccines
a cutting-edge manufacturing facility in India and other licensed territories. in preventing and treating infections to combat infectious diseases globally.”
The company has invested “This will be our 5th R&D centre. in partnership with European company, Alopexx would be entitled to a one-time caused by over 15 different pathogens.
Rs. 250-crore on the R&D Centre, We believe that this facility will enable KrKa. This upcoming facility and new upfront payment and milestone payments, Mr. Daniel Vlock, CEO of Alopexx,
which is spread over 2,00,000 square us to develop ground breaking solu- R&D facility together represents an as well as royalties on future sales of A phase I, fi rst-in-human trial has added, “This collaboration brings us
foot and equipped with modern labora- tions that will address unmet medical investment of Rs. 2,250-crore over the AV0328 in the licensed territories.” been completed, demonstrating that one step closer to addressing the criti-
tories and infrastructure. needs,” said Mr. Chava. next four years, creating 2,800 jobs. AV0328 is well tolerated, with no serious cal need for affordable, broad-spectrum
Alopexx, is a clinical-stage biotech- adverse events observed. The vaccine antimicrobial solutions, especially in
Strides Pharma secures approval for OneSource nology company focused on developing induced antibodies capable of killing low- and middle-income countries.”

CDMO creation Aragen Life Sciences gets SBTi approval for its

Strides Pharma Science Ltd. said sectors like biologics, complex inject- unlock value for Strides’ stakeholders GHG emission reduction targets
it has received approval from equity ables, and oral technologies. upon OneSource’s listing. Aragen Life Sciences, the Hydera- to achieving net-zero greenhouse Commenting on the approval,
shareholders and secured creditors to bad-based provider of contract research, gas emissions across its value chain Mr. Manni Kantipudi, CEO, Aragen Life
create OneSource, which it described The company plans to integrate its With stock exchange approvals development, and manufacturing ser- by FY2050. Sciences said, “This validation by the
as “India’s fi rst speciality pharma Con- Oral Technologies business with the obtained in May 2024, Strides will vices for the life sciences industries  Near-term targets: Reducing abso- SBTi is more than just a recognition of
tract Development and Manufacturing Sterile Injectables business of Steri- now seek fi nal approval from the announced that it has received approval lute Scope 1, 2 and 3 GHG emis- our efforts; it is a critical step forward in
Organisation (CDMO)”. Science Specialty Pvt. Ltd. and the bio- National Company Law Tribunal from the UK-based Science Based sions by 50.4% by FY2033 (base our sustainability journey. These targets
logics and high-end drug devices combi- (NCLT), Mumbai Bench. Upon receiving Targets initiative (SBTi) for its near- year FY2023). underscore our dedication to innova-
The approval is a crucial step nation business of OneSource (formerly NCLT approval, OneSource will pro- term and net-zero sustainability targets.  Long-term targets: Reducing abso- tion, collaboration, and transparency in a
towards establishing OneSource as an Stelis). This strategic move, fi rst ceed to seek listing approvals from the lute Scope 1, 2, and 3 GHG emis- holistic manner, while ensuring sustain-
independent entity covering advanced announced in September 2023, aims to BSE and NSE. The SBTi targets provide a scienti- sions by 90% by FY2050 (base year ability measures are in place as we work
fi cally backed framework for redu- FY2023). with the 400+ customers globally”.
Aurobindo Pharma arm’s injectable facility gets cing greenhouse gas (GHG) emissions, Silver Touch Technologies launches AI subsi-
USFDA nod in line with the 2015 Paris agreement. diary for pharma sector
SBTi has validated Aragen’s green-
house gas emission reduction targets
A new injectable facility of Pradesh, from March 28 to April 5. new drug application) was submitted as to conform with its criteria and recom- Silver Touch Technologies Ltd. Gujarat, aims to create AI-based tools
Aurobindo Pharma’s subsidiary, Eugia It has now received its fi rst product Prior Approval Supplement for addi- mendations, as outlined in Criteria has incorporated a new subsidiary, for regulatory submissions, monitoring,
Steriles, has received its fi rst product approval from the US-FDA for Lido- tion of an alternate drug product manu- version 5.1. AI4Pharma Tech Ltd., to develop arti- and compliance within the pharmaceu-
approval from the US FDA. The regu- caine Hydrochloride Injection, USP, facturing, labelling, packaging and fi cial intelligence (AI) solutions for the tical sector. Silver Touch Technologies
lator inspected the unit in Parawada 1% (10 mg/mL) and 2% (20 mg/mL). testing facility, Aurobindo Pharma said Aragen’s approved targets are: pharmaceutical industry. AI4Pharma has subscribed to 50.09% of the new
mandal of Anakapalli district, Andhra The sANDA (supplemental abbreviated in a regulatory fi ling.  Overall net-zero target: committed Tech Ltd., registered in Ahmedabad, entity’s share capital.

140 Chemical Weekly September 24, 2024 Chemical Weekly September 24, 2024 141

Contents Index to Advertisers Index to Products Advertised